Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
FETROJA (cefiderocol sulfate tosylate) is a siderophore cephalosporin antibiotic administered intravenously as a powder for reconstitution. It is indicated for serious gram-negative bacterial infections in patients with limited treatment options, particularly those resistant to conventional beta-lactams. The drug works by utilizing bacterial iron-uptake pathways to penetrate and disrupt cell wall synthesis in resistant organisms.
FETROJA is in peak commercial phase with 41 linked jobs, indicating an active but niche commercial organization focused on specialty hospital and infectious disease channels.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on FETROJA positions you in a specialized infectious disease/hospital space with significant quality, regulatory, and commercial infrastructure needs. Career growth trajectories include specialist hospital account management, sterile manufacturing leadership, and data/analytics roles supporting hospital formulary penetration.
Worked on FETROJA at Shionogi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
41 open roles linked to this drug
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo